Format

Send to

Choose Destination
J Biomed Res. 2016 Nov;30(6):441-451. doi: 10.7555/JBR.30.20150109. Epub 2015 Nov 10.

The more the messier: centrosome amplification as a novel biomarker for personalized treatment of colorectal cancers.

Author information

1
Department of Biology, Georgia State University, Atlanta, GA 30303, USA.
2
Novazoi Theranostics Inc., Plano, TX 75025, USA.
3
Institute of Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA.
4
Center for Obesity Research, Georgia State University, Atlanta, GA 30303, USA; raneja@gsu.edu.

Abstract

Colon cancer is currently the third most common cancer and second most fatal cancer in the United States, resulting in approximately 600,000 deaths annually. Though colorectal cancer death rates are decreasing by about 3% every year, disease outcomes could be substantially improved with more research into the drivers of colon carcinogenesis, the determinants of aggressiveness in colorectal cancer and the identification of biomarkers that could enable choice of more optimal treatments. Colon carcinogenesis is notably a slow process that can take decades. Known factors that contribute to the development of colon cancer are mutational, epigenetic and environmental, and risk factors include age, history of polyps and family history of colon cancer. Colorectal cancers exhibit heterogeneity in their features and are often characterized by the presence of chromosomal instability, microscopic satellite instability, or CpG island methylator phenotype. In this review, we propose that centrosome amplification may be a widespread occurrence in colorectal cancers and could potently influence tumor biology. Moreover, the quantitation of this cancer-specific anomaly could offer valuable prognostic information and pave the way for further customization of treatment based on the organellar profile of patients. Patient stratification models that take into account centrosomal status could thus potentially reduce adverse side effects and result in improved outcomes for colorectal cancer patients.

KEYWORDS:

aneuploidy; biomarker; centrosome amplification; chromosomal instability; colorectal cancer; prognostic

Conflict of interest statement

CLC number: R730.4, Document code: A The authors reported no conflict of interests.

Publication type

Publication type

Supplemental Content

Full text links

Icon for Journal of Biomedical Research Icon for PubMed Central
Loading ...
Support Center